Low VWF Levels Linked With Lower CVD Risk
People with low levels of von Willebrand factor (VWF) had a lower risk of incident cardiovascular disease (CVD), according to a study published in ...
Efgartigimod Promotes Sustained Platelet Count Response in iTP
Treatment with efgartigimod (EFG) resulted in platelet count increases as well as high sustained platelet count responses in patients with persistent or chronic immune thrombocytopenia (iTP) ...
Emicizumab Can Be Used Without FVIII Inhibitors in Infants With Severe Hemophilia
Results of an interim analysis of the HAVEN 7 study indicated that emicizumab is safe and effective in infants with severe hemophilia A without factor VIII (FVIII) inhibitors ...
Study Reveals Approach to Testing Adolescent Girls for VWD
An adolescent who is being evaluated for acute heavy menstrual bleeding and has von Willebrand factor (VWF) antigen levels of 80% or lower on initial presentation should have the test repeated at a later timepoint when she is back to her normal state of health ...
TA More Effective, Affordable Than rVWF for VWD-Related Heavy Menstrual Bleeding
Tranexamic acid (TA) may be the more effective and affordable option for reducing heavy menstrual bleeding among women with von Willebrand disease (VWD) compared to recombinant von Willebrand factor (rVWF) ...
Small Study Suggests Subcutaneous Rondoraptivon Pegol Improves VWF/FVIII Levels in Type 2B VWD
Treatment with the pegylated aptamer rondoraptivon pegol significantly improved levels of von Willebrand factor (VWF)/factor VIII (FVIII), multimer patterns, and thrombocytopenia in patients with type 2B von Willebrand disease (VWD), according to findings from a small phase II study...
Hemostatic Function Restored With Recombinant Porcine FVIII in Congenital Hemophilia A Samples
Porcine FVIII has been used in patients with hemophilia A and human FVIII inhibitors and was shown to be similar enough to achieve hemostatic functions of the human protein ...
Thromboelastography: Measuring Blood Coagulation in Real Time
The development of thromboelastography (TEG) in 1948 is credited to Dr. Helmut Hartert, who was working at the University of Heidelberg in Germany at the time. Also called a “viscoelastic assay,” this non-invasive test ...
Prophylactic TXA Does Not Prevent Bleeding in Thrombocytopenia From Hematologic Malignancy Treatment
Prophylactic tranexamic acid (TXA) did not decrease World Health Organization (WHO) grade ≥2 bleeding incidence or rates of platelet or red blood cell (RBC) transfusions in patients with thrombocytopenia ...
Switching to Nonacog Beta Pegol Reduces Bleeding Rates in Patients With Hemophilia B
Patients with hemophilia B who switched from recombinant factor IX-Fc-fusion protein (rFIXFc) or standard half-life (SHL) recombinant factor IX (rFIX) to nonacog beta pegol (N9-GP) experienced lower annualized rates of bleeding and reduced factor consumption ...
